<DOC>
	<DOCNO>NCT01462877</DOCNO>
	<brief_summary>Atherogenic dyslipidemia include patient coronary heart disease ( CHD ) CHD risk equivalent , whose TG level adequately control statin monotherapy . According publish ESC/EAS consensus , fibrate suggest added type patient insufficient improvement . The purpose study evaluate efficacy lipid control safety add fenofibrate patient background statin treatment .</brief_summary>
	<brief_title>A Study Evaluate Fenofibrate Combination With Statin Chinese Patients With Dyslipidemic</brief_title>
	<detailed_description>It open-label , single group , multi-center study . At around 30 investigate site , 500 dyslipidemic Chinese patient coronary heart disease ( CHD ) CHD risk equivalent , whose TG ≥1.70 mmol/L ( 150mg/dl ) &lt; 5.65mmol/L ( 500mg/dl ) least 2 month statin monotherapy standard dose enrol . After least 2 month statin monotherapy standard dose , patient high TG recruit give statin-fenofibrate combination therapy 8 week . Several lipid parameter safety parameter compare baseline , 4 week treatment 8 week treatment . Primary efficacy endpoint percentage TG decrease 8 week treatment . Secondary endpoint efficacy absolute change percent change TC , LDL-C , HDL-C , apoA1 , apoB apoB/apoA1 baseline , 4 week treatment 8 week treatment , absolute change percentage change hsCRP baseline 8 week treatment . Second endpoint safety incidence AE/SAE , change CK , ALT , AST , BUN Cr treatment number clinical meaningful abnormal change define ALT AST &gt; 3ULN , CK &gt; 10ULN , BUN &gt; 1.5ULN Cr &gt; 1.5ULN . Other Arm type self comparator</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . ≥18 year &lt; 80 year , male female 2 . With least one risk coronary heart disease ( CHD ) [ medical history myocardial infarction ( MI ) coronary angiography show coronary stenosis ≥ 50 % post percutaneous coronary intervention ( PCI ) post coronary artery bypass grafting ( CABG ) ] CHD risk equivalent , comprise , Other clinical form atherosclerotic disease ( ischemic stroke , peripheral arterial disease , abdominal aortic aneurysm , symptomatic carotid artery disease ) Type 2 Diabetes Multiple risk factor confer 10year risk CHD &gt; 20 % . 3 . ≥ 2 month statin monotherapy standard dose ( atorvastatin ≤20mg q.d . rosuvastatin ≤10mg q.d . simvastatin ≤40mg q.d . pravastatin ≤40mg q.d . pitavastatin ≤4mg q.d fluvastatin ≤80mg q.d . lovastatin ≤40mg q.d . ) plan continue previous type dose statin 4 . Triglycerides ( TG ) ≥1.70 mmol/L ( 150mg/dl ) TG &lt; 5.65 mmol/L ( 500mg/dl ) 5 . Subject must able provide inform consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , behalf , prior studyspecific procedure . 1 . Hypersensitive fenofibrate excipients 2 . Hepatic insufficiency [ alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2ULN ( upper limit normal ) ] 3 . Renal insufficiency [ Creatinine clearance rate ( Ccr ) &lt; 60ml/min estimate CockcroftGault equation Ccr= ( 140age ) *weight ( Kg ) *0.85 ( female ) / [ 0.818*Cr ( µmol/L ) ] 4 . Creatine kinase ( CK ) &gt; 2 ULN 5 . Congenital galactosemia , glucosegalactose malabsorption syndrome lactase deficiency 6 . Hypothyroidism 7 . Combination use nonstatin lipidregulating drug fibrates , niacin fish oil previous 2 month 8 . Combination use drug similar structure Fenofibrate , especially ketoprofen 9 . Combination use oral anticoagulant 10 . Pregnant lactate woman 11 . Other condition investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Lipid Regulating Agents</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Combination</keyword>
</DOC>